The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

By C. Jordan, D. Upchurch, S. Szilvassy, M. Guzman, D. Howard, A. Pettigrew, T. Meyerrose, R. Rossi, B. Grimes, D. Rizzieri and 2 more. Leukemia, 2000

857 citations recorded by the source corpus.

Subfields: Hematology, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/f79a934823e46c5429429ddbcbed06abf992bb64

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. R. Majeti
2. Irving L. Weissman
3. Siddhartha Jaiswal
4. M. Clarke
5. W. Pang

In Immunology

1. Irving L. Weissman
2. R. Majeti
3. W. Pang
4. M. Chao
5. M. Clarke
6. John Calvin Reed
7. Siddhartha Jaiswal
8. M. Soengas

In Oncology

1. M. Clarke
2. Irving L. Weissman
3. Dalong Qian
4. Y. Shimono
5. N. Lobo
6. Siddhartha Jaiswal
7. John Calvin Reed
8. M. Soengas

Citations in the corpus

• CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells (2009, background): “Several candidate molecules, including CD123 (Jordan et al., 2000), CD44 (Jin et al., 2006), CD96 (Hosen et al., 2007), CLL-1 (van Rhenen et al., 2007), and now CD47, have recently been identified.”
• Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. (2006, methodology): “AML stem cells have been CANCER CELL NOVEMBER 2006 phenotypically defined as CD34+382123+ (Jordan et al., 2000).”
• The biology of cancer stem cells. (2007, methodology): “Jordan and colleagues ( Jordan et al. 2000) have shown that two commonly used treatment agents, cytarabine and adriamycin, preferentially kill the leukemic blasts, whereas the LSCs are relatively resistant (Costello et al. 2000).”